Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $36.0 million.

  • Inhibrx Biosciences' Total Current Liabilities fell 18.40% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 18.40%. This contributed to the annual value of $40.7 million for FY2024, which is 27.67% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Total Current Liabilities stood at $36.0 million for Q3 2025, which was down 7.59% from $38.9 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Total Current Liabilities high stood at $56.3 million for Q4 2023, and its period low was $36.0 million during Q3 2025.
  • Moreover, its 3-year median value for Total Current Liabilities was $40.7 million (2024), whereas its average is $42.7 million.
  • Data for Inhibrx Biosciences' Total Current Liabilities shows a maximum YoY decreased of 27.67% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Total Current Liabilities (Quarterly) stood at $56.3 million in 2023, then fell by 27.67% to $40.7 million in 2024, then fell by 18.40% to $36.0 million in 2025.
  • Its last three reported values are $36.0 million in Q3 2025, $38.9 million for Q2 2025, and $43.6 million during Q1 2025.